Harry Ford

2.1k total citations
58 papers, 1.8k citations indexed

About

Harry Ford is a scholar working on Molecular Biology, Infectious Diseases and Epidemiology. According to data from OpenAlex, Harry Ford has authored 58 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Molecular Biology, 30 papers in Infectious Diseases and 28 papers in Epidemiology. Recurrent topics in Harry Ford's work include HIV/AIDS drug development and treatment (30 papers), Cytomegalovirus and herpesvirus research (23 papers) and Biochemical and Molecular Research (16 papers). Harry Ford is often cited by papers focused on HIV/AIDS drug development and treatment (30 papers), Cytomegalovirus and herpesvirus research (23 papers) and Biochemical and Molecular Research (16 papers). Harry Ford collaborates with scholars based in United States, Israel and Malaysia. Harry Ford's co-authors include Víctor E. Márquez, Hiroaki Mitsuya, James A. Kelley, M. Arshad Siddiqui, Terrence R. Burke, Clifford George, David G. Johns, Joseph J. Barchi, John S. Driscoll and Mark S. Smyth and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and The Journal of Immunology.

In The Last Decade

Harry Ford

58 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Harry Ford United States 24 1.2k 681 464 392 326 58 1.8k
Tai‐Shun Lin United States 24 1.1k 0.9× 548 0.8× 455 1.0× 232 0.6× 212 0.7× 51 2.0k
George W. Koszalka United States 24 1.2k 1.1× 593 0.9× 508 1.1× 855 2.2× 258 0.8× 56 2.4k
Krzysztof W. Pankiewicz United States 25 1.5k 1.3× 651 1.0× 611 1.3× 523 1.3× 94 0.3× 97 2.3k
Ginger E. Dutschman United States 32 1.4k 1.2× 1.3k 2.0× 555 1.2× 1.0k 2.6× 797 2.4× 88 3.1k
Kazuhiro Haraguchi Japan 25 1.0k 0.9× 575 0.8× 859 1.9× 243 0.6× 213 0.7× 120 1.9k
M. Arshad Siddiqui United States 27 1.4k 1.2× 558 0.8× 1.2k 2.5× 233 0.6× 162 0.5× 86 2.4k
Milena Masojı́dková Czechia 22 1.0k 0.9× 801 1.2× 910 2.0× 447 1.1× 134 0.4× 133 1.8k
Sue C. Shaddix United States 18 686 0.6× 444 0.7× 274 0.6× 184 0.5× 188 0.6× 35 1.3k
J P Sommadossi United States 21 774 0.7× 1.1k 1.6× 326 0.7× 666 1.7× 621 1.9× 49 2.0k
Noriaki Minakawa Japan 26 1.7k 1.4× 418 0.6× 662 1.4× 299 0.8× 60 0.2× 130 2.4k

Countries citing papers authored by Harry Ford

Since Specialization
Citations

This map shows the geographic impact of Harry Ford's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harry Ford with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harry Ford more than expected).

Fields of papers citing papers by Harry Ford

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harry Ford. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harry Ford. The network helps show where Harry Ford may publish in the future.

Co-authorship network of co-authors of Harry Ford

This figure shows the co-authorship network connecting the top 25 collaborators of Harry Ford. A scholar is included among the top collaborators of Harry Ford based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harry Ford. Harry Ford is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
2.
Noy, Roy, Zvi Ben‐Zvi, Fabio Candotti, et al.. (2002). Pharmacokinetics and organ distribution of N -methanocarbathymidine, a novel thymidine analog, in mice bearing tumors transduced with the herpes simplex thymidine kinase gene. Cancer Chemotherapy and Pharmacology. 50(5). 360–366. 8 indexed citations
3.
Huleihel, Mahmoud, Esther Manor, Alexander Konson, et al.. (2002). Metabolic pathways of N-methanocarbathymidine, a novel antiviral agent, in native and herpes simplex virus type 1 infected Vero cells. Antiviral Research. 55(1). 63–75. 39 indexed citations
4.
Agbaria, Riad, Fabio Candotti, James A. Kelley, et al.. (2001). Biosynthetic Ganciclovir Triphosphate: Its Isolation and Characterization from Ganciclovir-Treated Herpes Simplex Thymidine Kinase-Transduced Murine Cells. Biochemical and Biophysical Research Communications. 289(2). 525–530. 8 indexed citations
5.
Kelley, James A., Heping Zhang, Mark F. Kavlick, et al.. (2001). Fluorometric Determination of 2′-β-Fluoro-2′,3′-dideoxyadenosine 5′-Triphosphate, the Active Metabolite of a New Anti-Human Immunodeficiency Virus Drug, in Human Lymphocytes. Analytical Biochemistry. 288(1). 52–61. 6 indexed citations
6.
Wildner, Oliver, John C. Morris, Nicholas N. Vahanian, et al.. (1999). Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer. Gene Therapy. 6(1). 57–62. 141 indexed citations
7.
Márquez, Víctor E., Pamela Russ, M. Arshad Siddiqui, et al.. (1999). Conformationally Restricted Nucleosides. The Reaction of Adenosine Deaminase with Substrates Built on a Bicyclo[3.1.0]hexane Template. Nucleosides and Nucleotides. 18(4-5). 521–530. 30 indexed citations
8.
Sheikhnejad, Gholamreza, Judith K. Christman, A. Goddard, et al.. (1999). Mechanism of inhibition of DNA (cytosine C5)-methyltransferases by oligodeoxyribonucleotides containing 5,6-dihydro-5-azacytosine 1 1Edited by R. Huber. Journal of Molecular Biology. 285(5). 2021–2034. 68 indexed citations
9.
Ford, Harry, et al.. (1997). Reversed-phase high-performance liquid chromatographic determination of the new antitumor agent cyclopentenyl cytosine in biological fluids. Journal of Chromatography B Biomedical Sciences and Applications. 692(1). 169–179. 1 indexed citations
10.
Ahluwalia, Gurpreet S., John S. Driscoll, Harry Ford, & David G. Johns. (1996). Comparison of the DNA Incorporation in Human MOLT-4 Cells of Two 2′-β-Fluoronucleosides, 2′-β-Fluoro-2′,3′-dideoxyadenosine and Fialuridine. Journal of Pharmaceutical Sciences. 85(4). 454–455. 3 indexed citations
11.
Ford, Harry, John S. Driscoll, Hao Zhang, et al.. (1995). Reversal by cytidine of cyclopentenyl cytosine-induced toxicity in mice without compromise of antitumor activity. Biochemical Pharmacology. 49(2). 173–180. 5 indexed citations
12.
Politi, Pedro M., William Dahut, Harry Ford, et al.. (1995). Phase I clinical trial of continuous infusion cyclopentenyl cytosine. Cancer Chemotherapy and Pharmacology. 36(6). 513–523. 37 indexed citations
13.
Agbaria, Riad, Harry Ford, James A. Kelley, et al.. (1993). Measurement of Cyclopentenyl Cytosine 5′-Triphosphate in Vitro and in Vivo by Multidimensional High-Performance Liquid Chromatography. Analytical Biochemistry. 213(1). 90–96. 8 indexed citations
14.
Shirasaka, Takuma, Eiji Kojima, Shizuko Aoki, et al.. (1991). Escherichia coli mediated biosynthesis and in vitro anti-HIV activity of lipophilic 6-halo-2',3'-dideoxypurine nucleosides. Journal of Medicinal Chemistry. 34(5). 1606–1612. 29 indexed citations
15.
Surbone, Antonella, Harry Ford, James A. Kelley, et al.. (1990). Phase I and pharmacokinetic study of arabinofuranosyl-5-azacytosine (fazarabine, NSC 281272).. PubMed. 50(4). 1220–5. 15 indexed citations
16.
Ahluwalia, Gurpreet S., David A. Cooney, Michael J. Currens, et al.. (1990). Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the antiviral nucleoside 2′,3′-dideoxyguanosine. Biochemical and Biophysical Research Communications. 171(3). 1297–1303. 20 indexed citations
17.
Márquez, Víctor E., Christopher K. H. Tseng, Hiroaki Mitsuya, et al.. (1990). Acid-stable 2'-fluoro purine dideoxynucleosides as active agents against HIV. Journal of Medicinal Chemistry. 33(3). 978–985. 183 indexed citations
18.
Heideman, Richard L., Andrea Gillespie, Harry Ford, et al.. (1989). Phase I trial and pharmacokinetic evaluation of fazarabine in children.. PubMed. 49(18). 5213–6. 18 indexed citations
19.
Kassianides, Chris, Jay H. Hoofnagle, R.H. Miller, et al.. (1989). Inhibition of duck hepatitis B virus replication by 2′,3′-dideoxycytidine. Gastroenterology. 97(5). 1275–1280. 55 indexed citations
20.
Ford, Harry, C.-H. Chang, & Edward J. Behrman. (1979). Additions and Corrections - A Pair-Specific Osmium Reagent for Polynucleotides. Journal of the American Chemical Society. 101(13). 3707–3707. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026